AAAAAA

   
Results: 1-12 |
Results: 12
Phosphorylation of nucleoside analog antiretrovirals: A review for clinicians
Authors: Stein, DS Moore, KHP
Citation: Ds. Stein et Khp. Moore, Phosphorylation of nucleoside analog antiretrovirals: A review for clinicians, PHARMACOTHE, 21(1), 2001, pp. 11-34
Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours
Authors: Moodley, D Pillay, K Naidoo, K Moodley, J Johnson, MA Moore, KHP Mudd, PN Pakes, GE
Citation: D. Moodley et al., Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours, J CLIN PHAR, 41(7), 2001, pp. 732-741
The bioavailability of the novel nonnucleoside reverse transcriptase inhibitor GW420867X is unaffected by food in healthy male volunteers
Authors: Cass, LM Moore, KHP Dallow, NS Jones, AE Sisson, JR Prince, WT
Citation: Lm. Cass et al., The bioavailability of the novel nonnucleoside reverse transcriptase inhibitor GW420867X is unaffected by food in healthy male volunteers, J CLIN PHAR, 41(5), 2001, pp. 528-535
Metabolic disposition and pharmacokinetics of [C-14]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects
Authors: Sadler, BM Chittick, GE Polk, RE Slain, D Kerkering, TM Studenberg, SD Lou, Y Moore, KHP Woolley, JL Stein, DS
Citation: Bm. Sadler et al., Metabolic disposition and pharmacokinetics of [C-14]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects, J CLIN PHAR, 41(4), 2001, pp. 386-396
Pharmacokinetics and tolerability of GW420867X, a nonnucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteers
Authors: Moore, KHP Cass, LM Dallow, N Hardman, TC Jones, A Boyce, M Prince, WT
Citation: Khp. Moore et al., Pharmacokinetics and tolerability of GW420867X, a nonnucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteers, J CLIN PHAR, 41(10), 2001, pp. 1098-1105
Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor
Authors: Moore, KHP Cass, LM Dallow, N Hardman, TC Jones, A Boyce, M Prince, WT
Citation: Khp. Moore et al., Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor, EUR J CL PH, 56(11), 2001, pp. 805-811
Oral zidovudine during labor to prevent perinatal HIV transmission, Bangkok: tolerance and zidovudine concentration in cord blood
Authors: Bhadrakom, C Simonds, RJ Mei, JV Asavapiriyanont, S Sangtaweesin, V Vanprapar, N Moore, KHP Young, NL Hannon, WH Mastro, TD Shaffer, N
Citation: C. Bhadrakom et al., Oral zidovudine during labor to prevent perinatal HIV transmission, Bangkok: tolerance and zidovudine concentration in cord blood, AIDS, 14(5), 2000, pp. 509-516
A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza: Effects of formulation and route of administration
Authors: Peng, AW Hussey, EK Moore, KHP
Citation: Aw. Peng et al., A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza: Effects of formulation and route of administration, J CLIN PHAR, 40(3), 2000, pp. 242-249
Clinical pharmacokinetics of lamivudine
Authors: Johnson, MA Moore, KHP Yuen, GJ Bye, A Pakes, GE
Citation: Ma. Johnson et al., Clinical pharmacokinetics of lamivudine, CLIN PHARMA, 36(1), 1999, pp. 41-66
The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1
Authors: Moore, KHP Barrett, JE Shaw, S Pakes, GE Churchus, R Kapoor, A Lloyd, J Barry, MG Back, D
Citation: Khp. Moore et al., The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1, AIDS, 13(16), 1999, pp. 2239-2250
Lamivudine zidovudine as a combined formulation tablet: Bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption
Authors: Moore, KHP Shaw, S Laurent, AL Lloyd, P Duncan, B Morris, DM O'Mara, MJ Pakes, GE
Citation: Khp. Moore et al., Lamivudine zidovudine as a combined formulation tablet: Bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption, J CLIN PHAR, 39(6), 1999, pp. 593-605
Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials
Authors: Moore, KHP Yuen, GJ Hussey, EK Pakes, GE Eron, JJ Bartlett, JA
Citation: Khp. Moore et al., Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials, ANTIM AG CH, 43(12), 1999, pp. 3025-3029
Risultati: 1-12 |